What is the current price and daily change for AYA.AX stock?

AYA.AX stock is trading at **A$4.18** on 17 Jan 2026, up **4.24%** intraday. The day range is **A$4.00–A$4.34** with volume **865,338** shares, close to the average daily volume of **870,263**.

What does Meyka AI forecast for AYA.AX stock?

Meyka AI's forecast model projects **A$6.67** for AYA.AX stock by year‑end, implying **+59.57%** vs the current **A$4.18**. Forecasts are model projections and not guarantees; monitor earnings on **24 Feb 2026**.

What are the main risks for AYA.AX stock?

Main risks for AYA.AX stock are negative earnings (**EPS -0.18**), high R&D spending, slow commercial uptake of Salix, and regulatory timing. Liquidity and valuation premium (PB **21.10**) increase sensitivity to execution.

What trading approach suits AYA.AX stock on the ASX?

For AYA.AX stock, consider a layered entry with tight ATR‑based stops (**A$0.32**) and targets at **A$5.50** (conservative) and **A$6.67** (Meyka year target). Close monitoring of volume and the 24 Feb 2026 earnings release is essential.

AU Stocks

AYA.AX Artrya Limited ASX up 4.24% intraday 17 Jan 2026: AI diagnostic interest lifts trade

ByDanny Kontos January 17, 2026January 17, 2026

AYA.AX stock rose 4.24% intraday to A$4.18 on 17 Jan 2026 as buyers responded to renewed interest in Artrya Limited’s AI cardiac-imaging tool Salix. Volume reached 865,338 shares versus an average of 870,263, signaling real intraday participation. The move follows continued clinical adoption updates and a solid technical trend after the 50-day average at A$3.89 crossed above the 200-day average at A$2.10. Artrya reports next on 24 Feb 2026, a near-term catalyst for guidance and revenue progress for this ASX-listed healthcare software company.